Phase I study of ICRF-159 (NSC-129943) in human solid tumors.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011407:Propane / Q000009:adverse effects / Q000627:therapeutic use; D012156:Reticulocytes
D000970:Antineoplastic Agents; D006454:Hemoglobins; D010879:Piperazines; D011407:Propane